Recommended Dosing Regimens for Adalimumab and Secukinumab in Moderate-to-Severe Hidradenitis Suppurativa
For adalimumab, use 160 mg at week 0,80 mg at week 2, then 40 mg weekly starting at week 4; for secukinumab, use 300 mg at weeks 0,1,2,3, and 4, then every 4 weeks thereafter, with escalation to every 2 weeks if inadequate response.
Adalimumab Dosing (TNF-alpha Inhibitor)
Standard FDA-Approved Regimen
The established dosing for adalimumab in adults with moderate-to-severe HS follows a loading dose strategy 1, 2:
- Week 0: 160 mg subcutaneous (given as four 40 mg injections)
- Week 2: 80 mg subcutaneous (given as two 40 mg injections)
- Week 4 onward: 40 mg weekly subcutaneous maintenance
This regimen was validated in the PIONEER I and II trials, achieving HiSCR (Hidradenitis Suppurativa Clinical Response) rates of 42% vs 26% placebo (PIONEER I) and 59% vs 28% placebo (PIONEER II) at week 12 1, 3. Weekly dosing proved superior to every-other-week dosing (17.6% vs 9.6% response rate at week 16) 4.
Critical Dosing Considerations
Continue weekly dosing for at least 12 weeks before assessing response. Approximately 40% of week-12 non-responders achieved response by week 36 with continued weekly treatment 1, 5. However, patients showing no improvement or worsening by week 12 are unlikely to benefit from continued therapy.
Do not reduce to every-other-week dosing after achieving response. Among week-12 responders, nearly half lost response at week 36 despite weekly maintenance, compared to three-quarters who switched to placebo 5. The data clearly demonstrate that continuing weekly dosing maintains better outcomes than dose reduction (48.1% HiSCR at week 36 with weekly vs 46.2% with every-other-week) 5.
Dose Escalation Strategy
For inadequate responders on standard weekly dosing, escalate to 80 mg weekly. This is particularly relevant for patients with obesity (BMI >30), as adalimumab dosing is not weight-based unlike other TNF inhibitors 6. In a dual-center study of patients with median BMI 36.6 who failed standard dosing, escalation to 80 mg weekly resulted in improved HS-PGA scores (median 3.0 to 2.0, p=0.01), with all 5 patients achieving HiSCR and all 8 reporting symptom improvements 6, 7, 8.
Common pitfall: Discontinuing therapy too early. Nearly 40% of week-12 non-responders eventually responded by week 36 with continued treatment 1.
Secukinumab Dosing (IL-17A Inhibitor)
Standard FDA-Approved Regimen
Secukinumab dosing for moderate-to-severe HS in adults 9, 10:
- Weeks 0,1,2,3, and 4: 300 mg subcutaneous (given as one 300 mg injection or two 150 mg injections)
- Week 8 onward: 300 mg every 4 weeks
This loading regimen achieved HiSCR rates of 45% (SUNSHINE) and 42% (SUNRISE) vs 34% and 31% placebo at week 16 10.
Dose Escalation for Inadequate Response
If inadequate response on every-4-week dosing, escalate to 300 mg every 2 weeks 9. The SUNRISE trial demonstrated that every-2-week dosing achieved superior HiSCR rates (42% vs 31% placebo, p=0.015) compared to every-4-week dosing (46% vs 31% placebo, p=0.0022) 10. Responses were sustained through week 52 with favorable safety profiles.
Key advantage: Secukinumab every-2-week dosing showed rapid improvement in signs and symptoms with sustained response up to 52 weeks 10.
Pediatric Considerations
Adalimumab in Pediatrics
- Ages 12 and older: Recommend adalimumab (strong recommendation) 11
- Ages 2-11: Suggest adalimumab (conditional recommendation) 11
- Ages 6 and older: Suggest secukinumab (conditional recommendation) 11
The most recent 2025 North American guidelines provide these age-stratified recommendations, though adalimumab remains the preferred first-line biologic for adolescents 11.
Safety Monitoring
Both agents demonstrated acceptable safety profiles. For adalimumab, serious adverse event rates were ≤7.8% across dosing groups 4, 3. Secukinumab's most common adverse event was headache (8-12% across groups), with no study-related deaths 10. Standard TNF-inhibitor precautions apply: screen for tuberculosis, monitor for serious infections, and avoid live vaccines 1.
Common pitfall: Switching from weekly to every-other-week adalimumab after initial response leads to decreased efficacy. Maintain weekly dosing for optimal disease control 5.